Immunotherapeutic Rescue of Steroidogenic Function in Autoimmune Adrenocortical Failure: Pilot Study
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Peak serum cortisol, basal or post ACTH
研究概览
简要总结
This is a pilot study of B lymphocyte depletion therapy in an attempt to salvage adrenal steroidogenic capacity in ten subjects with early autoimmune Addison's disease. During the first twelve weeks of treatment, additional glucocorticoid therapy (prednisolone) will be given to ensure wellbeing and to rest the steroidogenic apparatus that is the target of the autoimmune attack. Glucocorticoids will be gradually withdrawn, in a controlled fashion, and adrenal function re-evaluated at 13, 26, 39 and 52 weeks. The primary endpoint will be restoration of steroidogenic function as judged by conventional endocrine indices of adrenocortical function. B cell depletion may ameliorate the autoimmune attack against adrenal cells, potentially allowing a state of immune tolerance to be restored with subsequent recovery of adrenal steroidogenic capacity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 65 Years(Child, Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clear evidence of primary adrenal failure (elevated ACTH, pigmentation, electrolyte disturbance)
- •Basal or stimulated cortisol <400 nmol/l but >100nmol/l
排除标准
- •Active viral infection, pregnancy or breast feeding, previous immunosuppression, diabetes, cardiorespiratory disease, renal failure, hepatic disease, cancer
- •Calcified or enlarged adrenals on CT scan, active TB
研究组 & 干预措施
1
Receiving active treatment
干预措施: Solu-medrone, Mabthera (Drug)
结局指标
主要结局
Peak serum cortisol, basal or post ACTH
时间窗: 13, 26, 39, 52 weeks from first treatment
次要结局
- 21-OHase antibodies(13, 26,39, 52 weeks)
研究者
SHS Pearce
Professor of Endocrinology
Newcastle University
